Study summary · research use only
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, the authors examined the tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose and on permeability and adhesion of mesenteric capillaries in Wistar rats with streptozotocin-induced diabetes mellitus. The abstract reports that oral pancragen produced what the authors describe as a pronounced hypoglycemic effect during treatment, and that intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium but did not modify capillary permeability. The authors interpret the results as indicating homeostatic and endothelioprotective effects of pancragen during the early period of diabetes mellitus. No numerical figures were provided in the abstract.
Abstract
The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus. Oral pancragen produced a pronounced hypoglycemic effect during treatment. Intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium, but did not modify capillary permeability. The results indicate homeostatic and endothelioprotective effects of pancragen during the early period of diabetes mellitus.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.